129 related articles for article (PubMed ID: 33151506)
1. ASO Author Reflections: CTNNB1 and Fusion Genes as Predictors for Recurrence in Resected Early-Stage Lung Adenocarcinoma.
Kim IA; Kim WS; Lee KY
Ann Surg Oncol; 2021 Jul; 28(7):3994-3995. PubMed ID: 33151506
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: Impact of Ground-Glass Opacity Components in Long-Term Survivors with Resected Lung Adenocarcinoma.
Shigefuku S; Shimada Y
Ann Surg Oncol; 2021 Jan; 28(1):157-158. PubMed ID: 33067744
[No Abstract] [Full Text] [Related]
3. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
Jeon JH; Kang CH; Kim HS; Seong YW; Park IK; Kim YT
Eur J Cardiothorac Surg; 2015 Mar; 47(3):556-62. PubMed ID: 24760387
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
Kneuertz PJ; Carbone DP; D'Souza DM; Shilo K; Abdel-Rasoul M; Zhao W; Williams TM; Jones D; Merritt RE
Lung Cancer; 2020 May; 143():60-66. PubMed ID: 32208298
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor gene mutation as risk factor for recurrence in patients with surgically resected lung adenocarcinoma: a matched-pair analysis.
Matsumura Y; Owada Y; Yamaura T; Muto S; Osugi J; Hoshino M; Higuchi M; Ohira T; Suzuki H; Gotoh M
Interact Cardiovasc Thorac Surg; 2016 Aug; 23(2):216-22. PubMed ID: 27173985
[TBL] [Abstract][Full Text] [Related]
6. Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
Matsumura Y; Suzuki H; Ohira T; Shiono S; Abe J; Sagawa M; Sakurada A; Katahira M; Machida Y; Takahashi S; Okada Y
Lung Cancer; 2017 Dec; 114():23-30. PubMed ID: 29173761
[TBL] [Abstract][Full Text] [Related]
7. Prediction of distant recurrence in resected stage I and II lung adenocarcinoma.
Aramini B; Casali C; Stefani A; Bettelli S; Wagner S; Sangale Z; Hughes E; Lanchbury JS; Maiorana A; Morandi U
Lung Cancer; 2016 Nov; 101():82-87. PubMed ID: 27794412
[TBL] [Abstract][Full Text] [Related]
8. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
9. Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation.
Ziv E; Erinjeri JP; Yarmohammadi H; Boas FE; Petre EN; Gao S; Shady W; Sofocleous CT; Jones DR; Rudin CM; Solomon SB
Radiology; 2017 Jan; 282(1):251-258. PubMed ID: 27440441
[TBL] [Abstract][Full Text] [Related]
10. Correlation of tumor spread through air spaces and clinicopathological characteristics in surgically resected lung adenocarcinomas.
Hu SY; Hsieh MS; Hsu HH; Tsai TM; Chiang XH; Tsou KC; Liao HC; Lin MW; Chen JS
Lung Cancer; 2018 Dec; 126():189-193. PubMed ID: 30527186
[TBL] [Abstract][Full Text] [Related]
11. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of basal versus superior segment in patients with completely resected lung adenocarcinoma in the lower lobe.
Lin YH; Hung JJ; Yeh YC; Hsu WH
Thorac Cancer; 2019 Feb; 10(2):312-320. PubMed ID: 30601596
[TBL] [Abstract][Full Text] [Related]
13. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients.
Kaduthanam S; Gade S; Meister M; Brase JC; Johannes M; Dienemann H; Warth A; Schnabel PA; Herth FJ; Sültmann H; Muley T; Kuner R
Lung Cancer; 2013 May; 80(2):223-7. PubMed ID: 23410826
[TBL] [Abstract][Full Text] [Related]
14. Identification of recurrence-associated microRNAs in stage I lung adenocarcinoma.
Sim J; Kim Y; Kim H; Shin SJ; Kim DH; Paik SS; Jang K
Medicine (Baltimore); 2018 Jun; 97(25):e10996. PubMed ID: 29923982
[TBL] [Abstract][Full Text] [Related]
15. Primary Lung Cribriform Adenocarcinoma With Squamoid Morules Harboring Somatic
Wu H; Ye Q; Razzano D; Tugal O; Rosenblum J; Weigel T; Zhong M
Pediatr Dev Pathol; 2020; 23(6):472-475. PubMed ID: 32924814
[TBL] [Abstract][Full Text] [Related]
16. Cancer. Attack of the clones.
Govindan R
Science; 2014 Oct; 346(6206):169-70. PubMed ID: 25301605
[No Abstract] [Full Text] [Related]
17. The prognostic value of a Methylome-based Malignancy Density Scoring System to predict recurrence risk in early-stage Lung Adenocarcinoma.
Yang L; Zhang J; Yang G; Xu H; Lin J; Shao L; Li J; Guo C; Du Y; Guo L; Li X; Han-Zhang H; Wang C; Chuai S; Ye J; Kang Q; Liu H; Ying J; Wang Y
Theranostics; 2020; 10(17):7635-7644. PubMed ID: 32685009
[TBL] [Abstract][Full Text] [Related]
18. Bleeding into a pulmonary cyst caused by pulmonary radiofrequency ablation.
Kishi R; Mimura H; Hiraki T; Gobara H; Uka M; Toyooka S; Kanazawa S
J Vasc Interv Radiol; 2013 Jul; 24(7):1069-71. PubMed ID: 23796097
[No Abstract] [Full Text] [Related]
19. Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis.
Ito M; Miyata Y; Tsutani Y; Ito H; Nakayama H; Imai K; Ikeda N; Okada M
Lung Cancer; 2020 Mar; 141():107-113. PubMed ID: 32035371
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Chemotherapy Improves the Probability of Freedom From Recurrence in Patients With Resected Stage IB Lung Adenocarcinoma.
Hung JJ; Wu YC; Chou TY; Jeng WJ; Yeh YC; Hsu WH
Ann Thorac Surg; 2016 Apr; 101(4):1346-53. PubMed ID: 26794883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
